various dosages of CS treatment were retrospectively studied in 210 patients.
Patients and methods
The data for all the patients who were diagnosed as having PMR or TA in our rheumatology department from January 1976 to December 1986 and who were closely followed up (until the last event relating to their disease) were Table 2 gives the results for the whole group. Temporal artery biopsy was performed on 56 patients. The evolution of PMR was not significantly different in the eight patients with positive temporal artery biopsy and the 48 patients with negative biopsy (Table 3) . tConcerns patients who achieved treatment withdrawal. in the TA group. The first category consists of patients who can be adequately treated with low doses of CS, i.e., a starting dose of prednisone of no more than 20 mg/d: higher doses increase the rate of adverse effects without providing any benefit; a slow decrease of CS dosage usually allows a withdrawal of the treatment two to three years later. The second category consists of patients affected with a more severe form of TA, in whom even high doses of CS are not always effective in preventing complications. The difficulty in recognising this second category is worrying. We found that men were more likely to experience TA complications than women (p<0-02). This worse prognosis attached to the male sex in TA has not been previously reported and needs to be confirmed.
The fear that PMR may be an underlying form of TA and the idea that high doses of CS ensured the best prevention against TA complications has led to a probably unjustified increase of CS dosage for treatment of both PMR and TA. This overtreatment is certainly harmful, especially in elderly people. Our study supports the idea that CS dosage can be reduced, but allowance must be made for its retrospective character. Until now, the starting dosage and the duration of CS treatment for PMR and TA were empirically determined. Controlled trials are needed to evaluate the results of low dosages of CS treatment for both PMR and TA.
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